SLC5A2 and chronic kidney disease: Based on the strong evidence of cardio-renal protection offered by the addition of finerenone to RAS inhibition observed in recent randomized controlled trials, we suggest in people with T2DM and CKD who have persistent albuminuria (ACR > 30 mg/mmol) despite the use of maximum tolerated doses of RAS inhibition and SGLT-2 inhibitors, to consider addition of finerenone.36